Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance

Mannu K. Walia, Patricia M.W. Ho, Scott Taylor, Alvin J.M. Ng, Ankita Gupte, Alistair M. Chalk, Andrew C.W. Zannettino, T. John Martin, Carl R. Walkley

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)


Mutations in the P53 pathway are a hallmark of human cancer. The identification of pathways upon which p53-deficient cells depend could reveal therapeutic targets that may spare normal cells with intact p53. In contrast to P53 point mutations in other cancer, complete loss of P53 is a frequent event in osteosarcoma (OS), the most common cancer of bone. The consequences of p53 loss for osteoblastic cells and OS development are poorly understood. Here we use murine OS models to demonstrate that elevated Pthlh (Pthrp), cAMP levels and signalling via CREB1 are characteristic of both p53-deficient osteoblasts and OS. Normal osteoblasts survive depletion of both PTHrP and CREB1. In contrast, p53-deficient osteoblasts and OS depend upon continuous activation of this pathway and undergo proliferation arrest and apoptosis in the absence of PTHrP or CREB1. Our results identify the PTHrP-cAMP-CREB1 axis as an attractive pathway for therapeutic inhibition in OS.

Original languageEnglish
Article numbere13446
Number of pages31
Issue numberApril 2016
Publication statusPublished - 12 Apr 2016
Externally publishedYes

Cite this